Funding Surge Flows into China's Innovative Drug Sector, Multiple Firms Secure Over RMB 100 Million in Recent Rounds

　　【Pharmaceutical Network Industry DynamicsSince 2025, the热度 of pharmaceutical financing in China has continued to rise. According to incomplete statistics, in April, there were 30 financing events for biopharmaceutical companies in China, most of which were earlier rounds of financing. There were 10 companies with financing exceeding 100 million yuan, with a total amount estimated to be over 1.5 billion yuan. Notably, from the current perspective, most companies' financing funds will mainly be used to advance innovative drug research and development.
 

On June 3, LongBio Pharma (Suzhou) Co., Ltd. ("LongBio") announced the completion of a Series C financing round exceeding 200 million yuan. This financing represents a crucial step toward the commercialization of its first innovative drug and will further accelerate the globalization of its pipeline. LongBio focuses on the research and development of macromolecular antibody drugs in the fields of allergy, complement, and autoimmune diseases, advancing innovative drug development through its antibody discovery, antibody engineering, and process development platforms.
 

The funds from this financing will be mainly used for the Phase III clinical trial and subsequent commercialization preparation of the core pipeline's next-generation anti-IgE antibody LP-003, as well as the Phase II clinical development of multiple indications for LP-005, the world’s first complement bispecific antibody. This will further consolidate LongBio's innovative advantages in the fields of allergy and complement diseases. Notably, within the past year, LongBio has successively completed its Series B2, B3, and C rounds of financing, with a cumulative financing amount exceeding 300 million yuan, highlighting the capital market's high recognition of its technical strength and commercial potential.
 

On May 29, AusperBio (Ausper Biopharma and AusperBio Therapeutics) announced the completion of a $50 million Series B+ financing round. The company is committed to the research and development of first-in-class and best-in-class targeted delivery small nucleic acid drugs. The proceeds from this financing will mainly be used to support the ongoing clinical development of its innovative antisense oligonucleotide drug AHB-137 for the functional cure of chronic hepatitis B (CHB), including the planned Phase 2 clinical trials to be conducted outside mainland China. In addition, the funds will also be utilized to expand commercial production partnerships and advance the expansion of the product pipeline to facilitate the company's long-term growth.
 

It is reported that AHB-137, a non-conjugated antisense oligonucleotide, has the potential to become a cornerstone for clinical cure of chronic hepatitis B. Currently, it is undergoing a Phase 1 international multicenter clinical trial and three Phase 2 clinical trials being conducted in China.
 

On May 20, CureGene, a company in Zhangjiang Science City, announced the completion of its over RMB100 million Series B+ financing round. CureGene focuses on the research and development of innovative drugs with global competitiveness. It has established a world-leading targeted prodrug and antiviral drug R&D technology platform, with multiple innovative drugs in its pipeline that possess global independent intellectual property rights and enormous market potential. The funds raised will be primarily invested in the clinical development of its core products in both China and the U.S., while simultaneously advancing the globalization of its innovative pipeline and accelerating the establishment of an internationally competitive R&D portfolio.
 

　　……
 

Overall, investment and financing in the biopharmaceutical field are becoming increasingly rational. Many well-established pharmaceutical companies with excellent R&D or performance have completed a new round of capital reserves. In the future, with financial support, the R&D progress of technologies, drugs, or candidate products by major biopharmaceutical enterprises is expected to accelerate further, bringing more new treatment options to patients.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.